---
title: "Opdivo (nivolumab) in metastatic non-small cell lung cancer: Pharmacology questions"
description: "Pharmacology questions on Opdivo (nivolumab) in metastatic non-small cell lung cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism and Pharmacokinetics. Questions: How do Opdivo and Yervoy work together? What does hyaluronidase do in Opdivo Qvantig? How quickly is Opdivo Qvantig absorbed after injection? How do Opdivo Qvantig levels compare with Opdivo IV (Checkmate 67T)? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/pharmacology"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab) in metastatic non-small cell lung cancer: Pharmacology questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)

Pharmacology questions that apply to every indication of Opdivo are on [Opdivo (nivolumab), all indications: Pharmacology](https://www.evicenter.com/medical-information/opdivo/pharmacology).

## Mechanism

<a id="opdivo-mechanism-with-yervoy"></a>

### How do Opdivo and Yervoy work together?

Applies to: First-line metastatic NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (PD-L1 ≥1%) or OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy

> “YERVOY in combination with OPDIVO harnesses the immune system to help destroy tumor cells and defend with memory cells.”

Source: [OPDIVO: Mechanism of Disease & Mechanism of Action, captured 2026-11-13](https://www.opdivohcp.com/moa#:~:text=YERVOY%20in%20combination%20with%20OPDIVO,and%20defend%20with%20memory%20cells.)

On the page, select: 1L METASTATIC NSCLC (PD-L1 ≥1%) OPDIVO + YERVOY® (ipilimumab)

> “OPDIVO helps existing T cells discover the tumor by blocking PD-1, an immune checkpoint. This process may also target normal cells.<sup>10-12</sup>
>
> YERVOY
>
> YERVOY blocks the immune checkpoint CTLA-4, which helps activate and proliferate cytotoxic T cells (that may infiltrate the tumor) and also suppresses Treg function.<sup>16,22</sup> This process may also target normal cells.<sup>16,22</sup> Some of the T cells stimulated by YERVOY can become memory T cells. Memory T cells may allow for a long-term immune response.<sup>14-19</sup>”

Source: [OPDIVO: Mechanism of Disease & Mechanism of Action, captured 2026-11-13](https://www.opdivohcp.com/moa#:~:text=OPDIVO%20helps%20existing%20T%20cells,allow%20for%20a%20long%2Dterm%20immune)

On the page, select: 1L METASTATIC NSCLC (PD-L1 ≥1%) OPDIVO + YERVOY® (ipilimumab)

<a id="opdivo-qvantig-hyaluronidase"></a>

### What does hyaluronidase do in Opdivo Qvantig?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “OPDIVO Qvantig is formulated with hyaluronidase to increase the dispersion and absorption of the subcutaneous delivery of nivolumab.<sup>1</sup> The nivolumab in OPDIVO Qvantig has the same mechanism of action as OPDIVO IV.<sup>1,2</sup> Nivolumab helps existing T cells discover the tumor by blocking PD-1, an immune checkpoint. This process may also target normal cells.<sup>1-4</sup>”

Source: [OPDIVO: FAQ's, captured 2026-11-13](https://www.opdivohcp.com/qvantig/faq#:~:text=OPDIVO%20Qvantig%20is%20formulated%20with,process%20may%20also%20target%20normal)

This passage is in a collapsed section of the page; select: How does OPDIVO Qvantig work?

> “Hyaluronan is a polysaccharide found in the extracellular matrix of the subcutaneous tissue. It is 
> depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural 
> components of the interstitial matrix, hyaluronan has a half-life of approximately 0.5 days. 
> Hyaluronidase increases permeability of the subcutaneous tissue by temporarily depolymerizing 
> hyaluronan. In the doses administered, hyaluronidase in OPDIVO QVANTIG acts transiently and 
> locally. The effects of hyaluronidase are reversible and permeability of the subcutaneous tissue 
> is restored within 24 to 48 hours.”

Source: [OPDIVO: OPDIVO Qvantig, page 27, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo-qvantig.pdf#page=27)

## Pharmacokinetics

<a id="opdivo-qvantig-absorption"></a>

### How quickly is Opdivo Qvantig absorbed after injection?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “Nivolumab bioavailability is 74% (14%). Peak concentrations occurred by approximately 6 days.”

Source: [OPDIVO: OPDIVO Qvantig, page 27, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo-qvantig.pdf#page=27)

> “Nivolumab steady state was achieved by 16 weeks. The systemic accumulation ratio was 2.3.”

Source: [OPDIVO: OPDIVO Qvantig, page 27, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo-qvantig.pdf#page=27)

<a id="opdivo-qvantig-pharmacokinetics"></a>

### How do Opdivo Qvantig levels compare with Opdivo IV (Checkmate 67T)?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “The pharmacokinetics of nivolumab were similar whether administered subcutaneously or by intravenous infusion.<sup>1,5</sup> The PK profile of OPDIVO Qvantig was studied in Checkmate 67T, a randomized, open-label, phase 3 noninferiority study vs nivolumab IV.<sup>1,5</sup>* The co-primary PK endpoints for noninferiority testing were time-averaged serum concentration over 28 days (Cavgd28) and the minimum serum concentration at steady-state (Cminss). The PK data from the trial are shown below.<sup>†</sup>”

Source: [OPDIVO: FAQ's, captured 2026-11-13](https://www.opdivohcp.com/qvantig/faq#:~:text=The%20pharmacokinetics%20of%20nivolumab%20were,from%20the%20trial%20are%20shown)

On the page, select: How do the pharmacokinetics of OPDIVO Qvantig compare to OPDIVO IV?

> “Co-primary PK endpoints<sup>1,5</sup>	OPDIVO Qvantig
> (n=242)	Nivolumab IV (n=245)	Geometric mean ratio<sup>‡</sup>
> (90% CI)
> Geometric mean Cavgd28, µg/mL (90% CI)	77.373
> (74.555–80.297)	36.875
> (35.565–38.235)	2.10
> (2.00–2.20)
> Geometric mean Cminss, µg/mL (90% CI)	122.227
> (114.552–130.416)	68.901
> (64.676–73.402)	1.77
> (1.63–1.93)”

Source: [OPDIVO: FAQ's, captured 2026-11-13](https://www.opdivohcp.com/qvantig/faq#:~:text=%28n%3D242%29,%281.63%E2%80%931.93%29)

On the page, select: How do the pharmacokinetics of OPDIVO Qvantig compare to OPDIVO IV?

> “*Checkmate 67T Study Information: Study design: Checkmate 67T was a phase 3, randomized (1:1), open-label, noninferiority trial evaluating OPDIVO Qvantig (1,200 mg of nivolumab and 20,000 units of hyaluronidase) compared with OPDIVO IV, in adult patients with advanced or metastatic ccRCC who received prior systemic therapy. Patients were stratified by weight (<80 kg vs ≥80 kg) and IMDC risk score (favorable vs intermediate vs poor risk). A total of 495 patients were randomized to receive either OPDIVO Qvantig every 4 weeks subcutaneously (n=248) or OPDIVO 3 mg/kg every 2 weeks intravenously (n=247). The co-primary endpoints were Cavgd28 and Cminss. The key powered secondary endpoint was ORR, as assessed by BICR. The minimum follow-up time was 8 months.<sup>1,5</sup>”

Source: [OPDIVO: FAQ's, captured 2026-11-13](https://www.opdivohcp.com/qvantig/faq#:~:text=%2ACheckmate%2067T%20Study%20Information%3A%20Study,minimum%20follow%2Dup%20time%20was%208)

On the page, select: How do the pharmacokinetics of OPDIVO Qvantig compare to OPDIVO IV?

> “<sup>†</sup>For both Cavgd28 and Cminss, the lower boundary of the 90% CI for the GMR was 0.8 or greater, the prespecified cut-off for noninferiority, indicating that these PK endpoints for OPDIVO Qvantig were noninferior to those for nivolumab IV.<sup>5</sup>”

Source: [OPDIVO: FAQ's, captured 2026-11-13](https://www.opdivohcp.com/qvantig/faq#:~:text=both%20Cavgd28%20and%20Cminss%2C%20the,noninferior%20to%20those%20for%20nivolumab)

On the page, select: How do the pharmacokinetics of OPDIVO Qvantig compare to OPDIVO IV?

Note: Checkmate 67T enrolled adults with previously treated advanced or metastatic clear cell renal cell carcinoma. The Opdivo HCP site cites its pharmacokinetic results in support of Opdivo Qvantig in previously treated metastatic NSCLC.

## Related pages
- [Medical information: Opdivo (nivolumab): Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)
- [Indication](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/guidelines)
